Small molecule drugs continue to be an important component of the drug development industry. Small molecules have been developed as effective ligands interacting with membrane receptors, ion channels and enzyme active sites. Their relatively small size (typically less than 600 daltons), compared to larger biologics, allows for better diffusion across cell membranes to reach intracellular targets. Further, they are generally stable and able to be administered orally, usually not immunogenic and are less complicated and costly to manufacture.
We use a variety of assays for ascertaining efficacy and toxicity questions with our clients’ small molecule compounds. We utilize these assays to understand the effects of a variety of compounds including anti-virals, HDAC inhibitors and kinase inhibitors.
Our assay services:
- Predict or evaluate myelosuppression and hematotoxicity using CFC assays
- Evaluate stimulatory or inhibitory hematological effects using CFC assays
- Evaluate additive or synergistic hematotoxicity of combination therapies
Click here for an overview of our cellPrism® assay platform.